The drug, delivered by EMS as a single injection, improved infarct-related patency at cath lab arrival and 30-day clinical outcomes.

Rapid treatment with CeleCor Therapeutics' investigational heart-attack drug, zalunfiban, resulted in higher levels of blood flow to the heart and an approximately 21% reduction in a patient's risk of ...

For optimal 1-year results, in patients with prior coronary artery bypass grafting who need percutaneous coronary ...

One year of treatment with either of two strong blood-thinning medications—ticagrelor and prasugrel—by people with type 1 or ...

Zalunfiban, a prehospital platelet inhibitor given by injection at the point of first medical contact for suspected STEMI, ...

A total of 282 patients at three sites in Switzerland and Canada were randomized one-to-one to IVL (n=142) and OPN (n=140).

How Metamaterial Design Could Give Interventional Cardiologists Finer Control in Complex Heart Surgeries Coronary artery disease afflicts 18 million ...

NEW ORLEANS, LA—Among patients with atrial fibrillation (AF) undergoing PCI, 1 month of dual therapy with a direct oral ...

After percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is recommended for 6 months in stable ...

Background: Observational studies have suggested that sodium-glucose cotransporter 2 inhibitors (SGLT2i) are associated with a lower risk of atrial fibrillation (AF) recurrence after catheter ablation ...

WE TURN TO FIVE ON YOUR HEALTH TONIGHT, AND A MAN WHO SUFFERED A STROKE AT JUST 29 YEARS OLD. SO YOUNG. WHAT DOCTORS ...

The practice of routinely maintaining PIVC access has not only benefits but also risks. It’s due for a mindset shift, with ...